Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 22;12(3):198. doi: 10.3390/toxins12030198

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effects of bvPLA2 treatment on Treg subpopulations in in vitro splenocyte cultures. (A) Splenocytes were stained with Treg cell phenotyping markers (CD4, CD25, Foxp3, CD62L, and CD127) and analyzed for Treg cell subsets by flow cytometry. Comparison of (B) resting Treg cell subsets (CD62LhiCD127low), (C) activated effector Treg cell subsets (CD62LlowCD127low), and (D) memory Treg cell subsets (CD62LlowCD127hi) based on expressions of CD62L and CD127 in PBS, bvPLA2, and rapamycin-treated splenocytes. Rapa, rapamycin. The data are shown as the means ± SEM. The significance was determined by one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05, ** p < 0.01, and *** p < 0.001 vs. the PBS group.